Background: Dried Plasma Spot (DPS) sampling in therapeutic drug monitoring (TDM) is a field of research in development. Compared with venous sampling, DPS sampling is a minimally invasive procedure where the patient's finger is pricked and only a small volume of blood is sampled. Plasma concentration of sunitinib, a small molecule multi-targeted tyrosine kinase inhibitor, has proven the correlation with its efficacy and toxicity. TDM-guided dose adjustment of sunitinib could contribute to minimize the toxicity and to maximize the efficacy. This study describes the development of DPS assay for sunitinib and its metabolite, using high performance liquid chromatography tandem mass spectrometry. Methods: Blood samplings of 4mL were performed 1-3 times from patients who were treated with sunitinib. DPS samples were prepared by applying 30 lL of spiked whole blood onto a Noviplex Card TM . Sunitinib and its metabolite were extracted with distilled water and methanol. The collected extract (3 lL) was injected onto a 100 mm Â 2.1 mm 3lm Mastro TM C18 column and eluted with acetonitrile gradient into a triple quadrupole ESI-MS/MS Shimadzu LCMS-8050. Deming regression and Bland-Altman analyses were used to determine the relation between calculated and measured plasma concentrations. The study protocol was approved by our institutional review board and informed consent was obtained from all patients. Results: Four patients with thymic carcinoma were entered in this study. DPS concentrations and plasma concentrations of both sunitinib and its metabolite showed a strong correlation (r ¼ 0.941 and 0.906, respectively). Subsequently, Bland-Altman analyses showed that 80% of sunitinib and 75% of its metabolite were within 6 20%, resulting in a high feasibility. Conclusions: We have firstly developed a DPS assay of sunitinib and its metabolite, which is a convenient simple method. Our DPS assay showed comparable results to plasma samples, and could be applicable in routine clinical practice. For the application of DPS cards for TDM use, we are planning a validation study which patients use DPS cards themselves. Oncology, Dharma Nugraha Hospital, Jakarta, Indonesia Background: Epidermal growth factor receptor (EGFR) family members are known to have important roles in breast cancer development. Clinical trials of EGFR tyrosine kinase inhibitor (TKI) in unselected breast cancer patients have not yielded promising results. Moreover, the presence of TKI-sensitive EGFR mutations may be rare and has not been clarified in different breast cancer subtypes in Indonesia. Methods: Direct DNA sequencing was used to determine specific EGFR mutations, namely L858R and L861Q informalin fixed paraffin embedded (FFPE) samples collected from 152 consecutive breast cancer patients treated in Dharmanugraha Hospital. The study was approved by Dharmanugraha ethics committee. The archived specimens comprised of luminal A (45%), triple-negative (27%), and HER2-positive subtypes (28%). Results: EGFR mutation, L858R and L861Q, was found in all subtypes of breast cancers. Overall prevalence of EGFR mutation L858R was 11.84% (18 of 152) and predominantly found in HER-2 positive subtype (13.95%), followed by TNBC subtype (12.20%) and luminal A subtype (10.29%). L861Q mutations were detected more frequently than L858R mutations (19.08% vs 11.84%, respectively). The L861Q mutation was found most frequently in luminal group (23.53%), followed by TNBC group (17.07%) and HER-2 positive group (13.95%). Conclusions: Tyrosine kinase inhibitor-sensitive EGFR mutations were present in all types of breast cancers. The incidence of EGFR mutation of L861Q was higher than L858R. The mutation of L858R was distributed almost evenly in all type of breast cancers. On the other hand, L861Q was commonly found in luminal group compared with two other groups. Indonesian breast cancer patients harboring TKI-sensitive mutations may be eligible for clinical trials evaluating TKI efficacy. Background: Targeted therapy is a promising treatment in oncogenic driven mutations of lung cancer. Thus exploration of molecular profile is the crucial factor to develop targeted drugs. The ethnicity might affect the molecular profile in each population. This study aims to demonstrate the unique molecular characteristic of lung adenocarcinoma in the Thai population. Methods: We studied 56 lung cancer patients' molecular profiles by using Next Generation Sequencing (NGS) for 45 genes lung cancer panel (Ion Torrent system) and confirmed the NGS findings by RT-PCR. Results: We found 14.3% (8/56) of BRAF (V600E mutation), 58.9% (33/56) of EGFR mutations, 30.4% (17/56) of KRAS mutations, 5.4% (3/56) of MET exon14 splice site and 3.6% (2/56) of AKT mutation (E17K) by NGS method using the allele fraction cutoff at 2%. After we confirmed BRAF, EGFR, and KRAS mutations by using RT-PCR then the prevalence of BRAF V600E, EGFR mutations, and KRAS mutations were 10.7%, 57.1%, and 3.6%, respectively. The false positive KRAS mutation by NGS method probably due to the detection of base changing from G to A which could be similar to the artifact of formalin fixation for G12D, G12S, G13D, and G13S. We also found 5 patients (8.9%) who had more than one mutation in each person as showed in 
